Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib

Matthias Pinter(Medical University of Vienna), Wolfgang Sieghart(Atitus Educação), Rudolf Stauber(Medical University of Graz), Birgit Grünberger(Fachhochschule Wiener Neustadt), Robert Königsberg(Kaiser-Franz-Josef-Spital), Christian Müller(Medical University of Vienna), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), A Maieron(Universitätsklinikum St. Pölten), Ivo Graziadei(Landeskrankenhaus Feldkirch), Claus Kölblinger(Russian State Agrarian Correspondence University), Wolfgang Vogel(Russian State Agrarian Correspondence University), Florian Hucke(Klinikum Klagenfurt)
Radiology
March 23, 2012
10.1148/radiol.12111550
Cited by 197

Related Papers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Meta‐analysis: <scp>ARFI</scp> elastography versus transient elastography for the evaluation of liver fibrosis
|Liver International|2013|417
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
|Blood|2000|322